Core Viewpoint - TianKang Biological reported a steady increase in revenue despite a decline in net profit, indicating resilience in a challenging market environment [1][4]. Financial Performance - For the first three quarters, the company achieved operating revenue of 13.61 billion yuan, a year-on-year increase of 4%, while net profit attributable to shareholders was 412 million yuan, down 27.2% [1]. - In Q3 alone, the operating revenue was 4.764 billion yuan, reflecting a quarter-on-quarter growth of 2.08%, marking three consecutive quarters of revenue growth [1]. Business Development - The company has developed multiple business lines, enhancing its competitive edge through cost advantages and efficient resource utilization [3]. - The protein oil business achieved record highs in raw material procurement, revenue, and profit for the 2024-2025 season, with raw material procurement reaching 950,000 tons and revenue of 2.5 billion yuan, exceeding targets by 136% and 137% respectively [3]. Feed Business - In the first nine months of 2025, the feed business sold 2.12 million tons, a year-on-year increase of 3.62%, with Q3 sales reaching 776,000 tons, up 11.8% year-on-year [3]. - The sales of pig feed in Q3 were 462,300 tons, showing an 18% increase year-on-year, while poultry feed sales were 165,500 tons, up 8% [3]. Cash Flow and Financial Health - The operating cash flow for the first three quarters was 2.351 billion yuan, a year-on-year increase of over 9%, indicating strong sales collection capabilities [4]. - The company's net assets increased to 7.17 billion yuan, a growth of 2.21%, and short-term borrowings decreased significantly by 31.2% to 2.225 billion yuan, improving the financial structure [4]. Market Conditions - The average market price for pigs was reported at 10.9 yuan/kg as of October 20, the lowest since 2022, which may lead to industry capacity reduction [4]. - The comprehensive cost of pig farming in Q3 was 12.78 yuan/kg, down from 13 yuan/kg in the first half of the year, indicating potential for further cost reductions [5]. Strategic Acquisitions - The company plans to acquire 51% of Qiangdu Livestock, a profitable breeding enterprise, which is expected to enhance cost optimization and operational efficiency [5].
天康生物:连续三个季度营业收入环比增长,现金流稳健向好,北向资金+基金大手笔加仓